OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	104
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	28
Monoclonal Gammopathy-Associated Neuropathy	28
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	24
Management of Chronic Myeloid Leukemia in Children and Young Adults	20
Treatment-Free Remission: the New Goal in CML Therapy	17
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	17
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	17
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	17
Value in Myeloma Care: Myth or Reality	15
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	14
Targeting Apoptosis in ALL	14
Challenges in Chronic Myeloid Leukemia Management in South America	14
Allogeneic Transplant for CMML	13
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	13
Prognostic and Predictive Models in Myelofibrosis	12
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic	12
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift	12
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	11
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	11
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies	11
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	10
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	10
How Do We Manage Chronic Lymphocytic Leukemia in India	10
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)	10

Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	9
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	9
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	8
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	8
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	8
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	8
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center	8
Avapritinib in the Treatment of Systemic Mastocytosis: an Update	7
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia	7
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	7
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	7
Myeloproliferative Neoplasms with Monocytosis	6
Pediatric Germline Predisposition to Myeloid Neoplasms	6
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	6
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	6
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	6
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	6
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	6
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	5
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	5
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	5
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	5
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	5
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	5
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	5
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	5
Real-world Management of CML: Outcomes and Treatment Patterns	4
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	4
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera	4
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	4
Managing Survivorship after Hematopoietic Cell Transplantation	4
Measurable Residual Disease Monitoring in Lymphoma	4
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	4